Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.37 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | MGAM | O43451 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | SI | P14410 | 1/20 | 0.34 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | CTSD | P07339 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NAAA | Q02083 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7888405 | 0.88 | BRD4 (0.41) | BRD4GLATSHRHSD17B10MGAM | |
| SCHEMBL18083628 | 0.88 | BRD4 (0.41) | BRD4GLATSHRHSD17B10MGAM | |
| SCHEMBL24197361 | 0.84 | BRD4 (0.50) | BRD4TSHRHSD17B10MGAMGAA | |
| SCHEMBL26647720 | 0.84 | BRD4 (0.50) | BRD4TSHRHSD17B10MGAMGAA | |
| SCHEMBL2036054 | 0.84 | — | — | |
| SCHEMBL22979625 | 0.83 | BRD4 (0.33) | BRD4GLAALDH1A1KMT2A | |
| Ammonia Solution, Strong SCHEMBL27687914 | 0.82 | — | — | |
| SCHEMBL868953 | 0.80 | BRD4 (0.47) | BRD4TSHREPHX2ALDH1A1KMT2A | |
| SCHEMBL3631878 | 0.80 | — | — | |
| SCHEMBL534088 | 0.80 | TSHR (0.45) | TSHRMGAMGAASIMGAM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250145621-A1 | 1H-PYRROLO[2,3-c]PYRIDIN-7(6H)-ONES AND PYRAZOLO[3,4-c]PYRIDIN-7(6H)-ONES AS INHIBITORS OF BET PROTEINS | INCYTE HOLDINGS CORPORATION | 2025-05-08 | — | — | US | disclosed |
| US-12227502-B2 | 1H-pyrrolo[2,3-c]pyridin-7(6H)-ones and pyrazolo[3,4-c] pyridin-7(6H)-ones as inhibitors of BET proteins | INCYTE CORPORATION (US) | 2025-02-18 | — | — | US | disclosed |
| US-20240254117-A1 | PYRIMIDO-HETEROCYCLIC COMPOUNDS, AND PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI RINGENE BIOPHARMA CO., LTD. (CN) | 2024-08-01 | — | — | US | disclosed |
| CN-114685487-B | Pyrimidine heterocyclic compounds, preparation method and application | 上海凌达生物医药有限公司 | 2024-04-19 | — | — | CN | disclosed |
| CN-114026097-B | Substituted pyrazoloquinazolinone compounds and uses thereof | 上海瑛派药业有限公司 | 2024-02-23 | — | — | CN | disclosed |
| US-20240002381-A1 | 1H-PYRROLO[2,3-c]PYRIDIN-7(6H)-ONES AND PYRAZOLO[3,4-c]PYRIDIN-7(6H)-ONES AS INHIBITORS OF BET PROTEINS | INCYTE CORPORATION | 2024-01-04 | — | — | US | disclosed |
| EP-4218766-A1 | 1H-PYRROLO[2,3-C]PYRIDIN-7(6H)-ONES AND PYRAZOLO[3,4-C]PYRIDIN-7(6H)-ONES AS INHIBITORS OF BET PROTEINS | Incyte Holdings Corporation (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-4218766-A1 | 1H-PYRROLO[2,3-C]PYRIDIN-7(6H)-ONES AND PYRAZOLO[3,4-C]PYRIDIN-7(6H)-ONES AS INHIBITORS OF BET PROTEINS | Incyte Holdings Corporation (US) | 2023-08-02 | — | — | EP | disclosed |
| US-11702416-B2 | 1H-pyrrolo[2,3-c]pyridin-7(6H)-ones and pyrazolo[3,4-c]pyridin-7(6H)-ones as inhibitors of BET proteins | INCYTE CORPORATION (US) | 2023-07-18 | — | — | US | disclosed |
| US-11702416-B2 | 1H-pyrrolo[2,3-c]pyridin-7(6H)-ones and pyrazolo[3,4-c]pyridin-7(6H)-ones as inhibitors of BET proteins | INCYTE CORPORATION (US) | 2023-07-18 | — | — | US | disclosed |
| EP-1641771-A1 | HYDROXAMATE SULFONAMIDES AS CD23 SHEDDING INHIBITORS | Celltech R & D Limited (GB) | 2006-04-05 | — | — | EP | disclosed |
| WO-2005116002-A2 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | AMGEN INC. (US) | 2005-12-08 | — | — | WO | disclosed |
| WO-2005014555-A1 | 4,5-DIHYDRO-IMIDAZOLE AS P2X7 ION CHANNEL BLOCKERS | AVENTIS PHARMACEUTICALS INC. (US) | 2005-02-17 | — | — | WO | disclosed |
| US-20050026916-A1 | Heterocyclic compounds as P2X7 ion channel blockers | AVENTIS PHARMACEUTICALS INC. (US) | 2005-02-03 | — | — | US | disclosed |
| WO-2004113298-A1 | HYDROXAMATE SULFONAMIDES AS CD23 SHEDDING INHIBITORS | CELLTECH R & D LIMITED (GB) | 2004-12-29 | — | — | WO | disclosed |
| WO-2004113312-A1 | HYDROXAMATE SULFONAMIDES AS CD23 SHEDDING INHIBITORS | CELLTECH R & D LIMITED (GB) | 2004-12-29 | — | — | WO | disclosed |
| US-20040242928-A1 | Tumor necrosis factor converting enzyme inhibitor; antiarthritic agents; lupus; Crohn's disease; multiple sclerosis; antidiabetic agents; infections;; asthma; skin disorders; anemia | STUDOR S.A. (LU) | 2004-12-02 | — | — | US | disclosed |
| EP-1431285-A1 | REVERSE HYDROXAMIC ACID DERIVATIVES | Kaken Pharmaceutical Co., Ltd. (JP) | 2004-06-23 | — | — | EP | disclosed |
| US-20040063698-A1 | Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-01 | — | — | US | disclosed |
| WO-2004012663-A2 | HYDANTOIN DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-ALPHA CONVERTING ENZYME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240002381-A1 | 1H-PYRROLO[2,3-c]PYRIDIN-7(6H)-ONES AND PYRAZOLO[3,4-c]PYRIDIN-7(6H)-ONES AS INHIBITORS OF BET PROTEINS | BRD3, BRD1, BRD2 | BRD4 4/4885GLA 4701/4885TSHR 2488/4885 |
| US-20250145621-A1 | 1H-PYRROLO[2,3-c]PYRIDIN-7(6H)-ONES AND PYRAZOLO[3,4-c]PYRIDIN-7(6H)-ONES AS INHIBITORS OF BET PROTEINS | BRD3, BRD1, BRD2 | BRD4 4/4885GLA 4701/4885TSHR 2488/4885 |
| US-11702416-B2 | 1H-pyrrolo[2,3-c]pyridin-7(6H)-ones and pyrazolo[3,4-c]pyridin-7(6H)-ones as inhibitors of BET proteins | BRD3, BRD1, BRD2 | BRD4 4/4885GLA 4701/4885TSHR 2488/4885 |
| US-20240254117-A1 | PYRIMIDO-HETEROCYCLIC COMPOUNDS, AND PREPARATION METHOD THEREFOR AND USE THEREOF | TYMS, TYMP, SLC5A11 | BRD4 4065/4885GLA 3557/4885TSHR 2811/4885 |
| US-20040242928-A1 | Tumor necrosis factor converting enzyme inhibitor; antiarthritic agents; lupus; Crohn's disease; multiple sclerosis; antidiabetic agents; infections;; asthma; skin disorders; anemia | TNF, RNASE1, IFNAR1 | BRD4 2485/4885GLA 75/4885TSHR 232/4885 |
| US-20050026916-A1 | Heterocyclic compounds as P2X7 ion channel blockers | P2RX3, P2RX2, P2RX5 | BRD4 421/4885GLA 3915/4885TSHR 1167/4885 |
| US-20040063698-A1 | Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme | MMP9, ADAM17, MMP3 | BRD4 2345/4885GLA 238/4885TSHR 2438/4885 |
| US-12227502-B2 | 1H-pyrrolo[2,3-c]pyridin-7(6H)-ones and pyrazolo[3,4-c] pyridin-7(6H)-ones as inhibitors of BET proteins | BRD3, BRD1, BRD2 | BRD4 4/4885GLA 4701/4885TSHR 2488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.